

Eirini I Rigopoulou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8128130/publications.pdf>

Version: 2024-02-01

97
papers

3,445
citations

117625

34
h-index

161849

54
g-index

99
all docs

99
docs citations

99
times ranked

3371
citing authors

#	ARTICLE	IF	CITATIONS
1	Twin studies in autoimmune disease: Genetics, gender and environment. <i>Journal of Autoimmunity</i> , 2012, 38, J156-J169.	6.5	233
2	Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. <i>Gastroenterology</i> , 2002, 122, 614-624.	1.3	180
3	Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. <i>Journal of Hepatology</i> , 2011, 55, 636-646.	3.7	163
4	<i>Helicobacter pylori</i> and autoimmune disease: Cause or bystander. <i>World Journal of Gastroenterology</i> , 2014, 20, 613.	3.3	130
5	Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2004, 40, 31-39.	3.7	128
6	Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its <i>Lactobacillus</i> mimic. <i>Hepatology</i> , 2005, 42, 458-465.	7.3	116
7	Infectome: A platform to trace infectious triggers of autoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 726-740.	5.8	94
8	Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity. <i>Hepatology</i> , 2005, 42, 1028-1036.	7.3	90
9	Blocking of interleukin-10 receptor—a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. <i>Clinical Immunology</i> , 2005, 117, 57-64.	3.2	86
10	Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: Lost and found. <i>Autoimmunity Reviews</i> , 2012, 12, 260-269.	5.8	81
11	DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2018, 23, 677-685.	1.0	68
12	Disease-specific cross-reactivity between mimicking peptides of heat shock protein of <i>mycobacterium gordonae</i> and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2004, 22, 353-362.	6.5	64
13	Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score?. <i>Digestive and Liver Disease</i> , 2010, 42, 807-812.	0.9	63
14	Autoimmunity and Environment: Am I at risk?. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 199-212.	6.5	60
15	Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. <i>Autoimmunity Reviews</i> , 2011, 11, 143-148.	5.8	59
16	Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. <i>Liver International</i> , 2007, 27, 1226-1231.	3.9	56
17	Diagnostic Relevance and Clinical Significance of the New Enhanced Performance M2 (MIT3) ELISA for the Detection of IgA and IgG Antimitochondrial Antibodies in Primary Biliary Cirrhosis. <i>Journal of Clinical Immunology</i> , 2007, 27, 378-387.	3.8	56
18	Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. <i>Clinical Immunology</i> , 2006, 119, 203-212.	3.2	53

#	ARTICLE	IF	CITATIONS
19	Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. <i>Hepatology</i> , 2007, 45, 1583-1583.	7.3	51
20	Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2005, 24, 251-260.	6.5	49
21	Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , 2012, 413, 1211-1216.	1.1	48
22	Occult hepatitis B virus infection in patients with autoimmune liver diseases. <i>Liver International</i> , 2009, 29, 434-442.	3.9	47
23	HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: Results from five hemodialysis units in central Greece. <i>Journal of Clinical Virology</i> , 2005, 34, 81-85.	3.1	45
24	Epstein-Barr Virus as a Trigger of Autoimmune Liver Diseases. <i>Advances in Virology</i> , 2012, 2012, 1-12.	1.1	43
25	Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 110-121.	1.5	42
26	p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: Lessons to learn from ANCA vasculitis and pemphigus vulgaris. <i>Autoimmunity Reviews</i> , 2013, 12, 580-590.	5.8	41
27	Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. <i>Annals of Hepatology</i> , 2014, 13, 127-135.	1.5	40
28	Primary Biliary Cirrhosis Associated with Systemic Sclerosis: Diagnostic and Clinical Challenges. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-12.	1.6	39
29	Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2005, 42, 393-399.	3.7	38
30	Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 118-126.	2.0	38
31	IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases. <i>Journal of Clinical Immunology</i> , 2008, 28, 501-511.	3.8	37
32	Sex Differences Associated with Primary Biliary Cirrhosis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	37
33	Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. <i>European Journal of Internal Medicine</i> , 2017, 42, 81-88.	2.2	37
34	Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. <i>World Journal of Gastroenterology</i> , 2010, 16, 225.	3.3	36
35	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. <i>Annals of Hepatology</i> , 2012, 11, 7-14.	1.5	36
36	Tracing environmental markers of autoimmunity: introducing the infectome. <i>Immunologic Research</i> , 2013, 56, 220-240.	2.9	35

#	ARTICLE	IF	CITATIONS
37	Assessment of health related quality of life in polish patients with primary biliary cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 471-479.	1.5	35
38	Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clinica Chimica Acta, 2007, 380, 118-121.	1.1	34
39	Primary Biliary Cirrhosis: Family Stories. Autoimmune Diseases, 2011, 2011, 1-11.	0.6	34
40	Autoantibodies in Autoimmune Pancreatitis. International Journal of Rheumatology, 2012, 2012, 1-8.	1.6	34
41	Oxidative stress and antioxidant status in patients with autoimmune liver diseases. Redox Report, 2015, 20, 33-41.	4.5	34
42	PBC Triggers in Water Reservoirs, Coal Mining Areas and Waste Disposal Sites: From Newcastle to New York. Disease Markers, 2010, 29, 337-344.	1.3	31
43	Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis. Liver International, 2015, 35, 1764-1771.	3.9	31
44	Recipient HLA-DR3, tumour necrosis factor- β promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are inter-related risk factors for chronic rejection of liver grafts. Journal of Hepatology, 2001, 34, 711-715.	3.7	30
45	Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. Journal of Autoimmunity, 2005, 25, 283-288.	6.5	29
46	PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Disease Markers, 2010, 29, 337-44.	1.3	26
47	Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. Immunity and Ageing, 2011, 8, 12.	4.2	25
48	Alterations of leptin during IFN- β therapy in patients with chronic viral hepatitis. Journal of Hepatology, 2006, 44, 848-855.	3.7	24
49	Molecular diagnostics of primary biliary cirrhosis. Expert Opinion on Medical Diagnostics, 2008, 2, 621-634.	1.6	23
50	Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus. Liver International, 2004, 24, 90-97.	3.9	22
51	Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. Journal of Autoimmune Diseases, 2007, 4, 2.	1.0	22
52	Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What's New?. Current Infectious Disease Reports, 2013, 15, 14-24.	3.0	22
53	Development of antimitochondrial antibodies in patients with autoimmune hepatitis: Art of facts or an artifact?. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 454-455.	2.8	21
54	Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Research, 2007, 75, 36-42.	4.1	21

#	ARTICLE	IF	CITATIONS
55	Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes. <i>Diabetes Research and Clinical Practice</i> , 2007, 77, 155-156.	2.8	20
56	Immune responses against <i>Helicobacter pylori</i> -specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis. <i>Scientific Reports</i> , 2017, 7, 7929.	3.3	20
57	Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. <i>Cancers</i> , 2021, 13, 1023.	3.7	20
58	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. <i>Annals of Hepatology</i> , 2012, 11, 7-14.	1.5	20
59	Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. <i>European Journal of Internal Medicine</i> , 2009, 20, 35-43.	2.2	18
60	Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , 2010, 411, 411-415.	1.1	18
61	Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 84-93.	1.5	18
62	Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 425-428.	1.6	17
63	Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: Revealing the unforeseen. <i>Clinica Chimica Acta</i> , 2006, 373, 183-184.	1.1	17
64	Risk factors associated with HCV infection in semi-rural areas of central Greece. <i>European Journal of Internal Medicine</i> , 2007, 18, 48-55.	2.2	17
65	Primary biliary cirrhosis and Henoch-Schönlein purpura: report of two cases and review of the literature. <i>Liver International</i> , 2007, 27, 280-283.	3.9	17
66	Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. <i>World Journal of Hepatology</i> , 2013, 5, 577.	2.0	17
67	Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis. <i>Autoimmunity Highlights</i> , 2013, 4, 1-9.	3.9	16
68	Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. <i>Annals of Hepatology</i> , 2013, 13, 127-35.	1.5	16
69	Impact on follow-up strategies in patients with primary sclerosing cholangitis. <i>Liver International</i> , 2023, 43, 127-138.	3.9	15
70	Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. <i>European Journal of Internal Medicine</i> , 2021, 85, 86-91.	2.2	13
71	CUZD1 and Anti-CUZD1 Antibodies as Markers of Cancer and Inflammatory Bowel Diseases. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.	3.3	12
72	Salmonella enteritidis Infection Complicated by Acute Myocarditis: A Case Report and Review of the Literature. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-6.	1.1	11

#	ARTICLE	IF	CITATIONS
73	Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?. World Journal of Gastroenterology, 2012, 18, 4855.	3.3	11
74	PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017003.	1.3	10
75	Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e25-e32.	1.5	10
76	Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and \hat{I}^3 -immunoglobulin infusions. World Journal of Clinical Cases, 2019, 7, 3394-3406.	0.8	9
77	Reversion of severe hepatopulmonary syndrome in a non cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: A case report and review of the literature. World Journal of Gastroenterology, 2006, 12, 336.	3.3	9
78	Self-mimicking autoimmune domains of hepatitis C virus core antigen. Vaccine, 2006, 24, 6173-6174.	3.8	8
79	Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. Autoimmunity Highlights, 2012, 3, 1-9.	3.9	8
80	Crohnâ€™s disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: Implications for the pathogenesis of the human disease. Autoimmunity, 2013, 46, 388-394.	2.6	7
81	Bone marrow findings in patients with autoimmune liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e416-21.	2.8	6
82	Flow Cytometric Detection of p38 MAPK Phosphorylation and Intracellular Cytokine Expression in Peripheral Blood Subpopulations from Patients with Autoimmune Rheumatic Diseases. Journal of Immunology Research, 2014, 2014, 1-13.	2.2	6
83	Lack of association between appendectomy and primary biliary cirrhosis. Scandinavian Journal of Gastroenterology, 2006, 41, 573-576.	1.5	5
84	Fetomaternal alloimmunity as a cause of liver disease. Autoimmunity Highlights, 2011, 2, 21-28.	3.9	5
85	Polymorphisms of IL12RB2 May Affect the Natural History of Primary Biliary Cholangitis: A Single Centre Study. Journal of Immunology Research, 2017, 2017, 1-5.	2.2	5
86	Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis. World Journal of Gastroenterology, 2020, 26, 246-265.	3.3	5
87	Popular and unpopular infectious agents linked to primary biliary cirrhosis. Autoimmunity Highlights, 2012, 3, 95-104.	3.9	4
88	Crohn's disease-specific anti-CUZD1 pancreatic antibodies are absent in ruminants with paratuberculosis. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 384-390.	1.5	4
89	Autoimmune hepatitis: Of host and pathogen. Hepatology, 2008, 47, 2147-2148.	7.3	3
90	Is primary biliary cirrhosis rare or common? The truth lies somewhere in between. Liver International, 2014, 34, e165-7.	3.9	3

#	ARTICLE	IF	CITATIONS
91	Can mathematical models be useful in clinical hepatology?. Liver International, 2010, 30, 637-638.	3.9	2
92	Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature. Tuberculosis Research and Treatment, 2012, 2012, 1-10.	0.6	2
93	Ascites in a patient with episodic angio-oedema and eosinophilia: thinking outside the box. BMJ Case Reports, 2017, 2017, bcr-2017-219467.	0.5	2
94	Diagnostic Discordance for Hepatitis C Virus Infection in Hemodialysis: Correlations with Clinical and Laboratory Features. American Journal of Kidney Diseases, 2005, 46, 992-993.	1.9	1
95	Infection and Autoimmune Liver Diseases. , 2015, , 839-857.		0
96	p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 52-60.	2.0	0
97	The changing epidemiology of hepatitis B in Greece. Annals of Gastroenterology, 2021, 34, 431-437.	0.6	0